A qualified computer engineering graduate, Akshay Kedari holds a commensurate passion for both writing and programming. Presently, Akshay develops content for healthcareopportunity.org and similar other portals. Apart from penning down pieces related to digitized healthcare, pharmaceuticals, and more, Akshay spends his free time enjoying bike rides and good food. He can be contacted at- [email protected] | https://twitter.com/axeyked
Francisco Partners (FP), a leading American technology-focused private equity (PE) firm, has reportedly acquired Qualcomm Life Inc., which is a wholly-owned subsidiary of Qualcomm Incorporated, that provides medical device …
UK’s drug discovery biotechnology company focusing on immune-oncology, Grey Wolf Therapeutics, recently announced that it has completed a £10 million series A financing round with the leading investors in …
The drug has specifically been developed for treating acquired Thrombotic Thrombocytopenic Purpura in adult patients. Cablivi’s efficacy was studied in a clinical trial which saw participation from over 145 …
Swisshealthcare company Roche will reportedly be donating its new hemophilia A drugHemlibra for a World Hemophilia Federation program, the company said.Apparently, Roche will be joining its rivals who also …
In close collaboration with WARF, Invenra’s SNIPER™ technology is expected to help create antibody-based therapies to advance pediatric neuroblastoma treatment Invenra, a Wisconsin-based biotechnology company, has reportedly entered into …
The Breakthrough Therapy Designation program is specifically designed to accelerate the development & review for medications designed for life-threatening conditions. The vaccine received the designation for facilitating the prevention …
Dewpoint Therapeutics, a biopharma company that translates the evolving area of biomolecular condensates into drug discovery, has recently announced its debut with USD 60 million in a series A …
Advent would be making a strategic investment in BioDuro to consolidate its position as a leading drug discovery & development services provider. The financial terms related to the partnership …
TG Therapeutics Inc., a U.S. based health care firm, has recently announced that its umbralisib (TGR-1202) treatment has been granted the Breakthrough Therapy Designation by the U.S. Food and …
Vertex Pharmaceuticals (Europe) Ltd. has reportedly announced that the European Commission has approved of the label extension for ORKAMBI. A lumacaftor/ivacaftor, ORKAMBI has been deemed safe for the treatment …
